SCHEDULE 13G/A: Ridgeback Capital Divests Entire Stake in Affimed N.V., Beneficial Ownership Drops to Zero
Schedule 13G Amendment
Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC have filed an amendment to their Schedule 13G, reporting a complete divestment of their beneficial ownership in Affimed N.V., now holding 0.0% of common shares.
Summary
- Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC (collectively, the "Reporting Persons") have filed Amendment No. 4 to their Schedule 13G.
- The filing indicates that the Reporting Persons no longer beneficially own any common shares of Affimed N.V., with their aggregate beneficial ownership reported as 0.0%.
- This amendment signifies a complete divestment of their previously reportable stake in Affimed N.V.
- The event requiring this filing occurred on May 16, 2025, with the statement filed on May 20, 2025.
- The Reporting Persons disclaim beneficial ownership of any securities covered by this statement, except to the extent of any pecuniary interest therein.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative as a significant investment entity, Ridgeback Capital, has completely divested its stake in Affimed N.V., which could be interpreted by the market as a lack of confidence or a strategic exit by a notable investor.
Negatives
- The complete divestment of shares by Ridgeback Capital, a notable investment entity, could be perceived as a negative signal regarding their confidence in Affimed N.V.'s future prospects.
Future Outlook
The document does not contain any forward-looking statements or guidance from Affimed N.V. or the Reporting Persons regarding the issuer's future performance.
Management Comments
- Nicole Venezia, General Counsel for Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
This filing reflects a change in an institutional investor's position within the biotechnology or pharmaceutical sector, where Affimed N.V. operates. Such divestments by investment firms are common portfolio management activities but can sometimes signal a shift in investor sentiment towards a specific company or the broader industry.
Stakeholder Impact
- Shareholders: May view the complete divestment by Ridgeback Capital as a negative signal, potentially impacting investor confidence and share price.
- Company Management: May need to address market perceptions related to the exit of a significant investor.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of event which required the filing of this statement (reduction of beneficial ownership to 0.0%). |
| 05/20/2025 | Date the Schedule 13G Amendment No. 4 was signed and filed. |
Keywords
Affimed N.V., Ridgeback Capital, Schedule 13G, Beneficial Ownership, Divestment, Common Shares, SEC Filing, Investment Firm, Shareholding Change
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.